OTC Monograph User Fees Inspire Wary Support From Industry
This article was originally published in The Tan Sheet
Executive Summary
Executives from OTC drug manufacturers list numerous doubts about the equity and effectiveness of a potential program that would impose user fees on firms that make or market monograph drugs, the vast majority of nonprescription pharmaceutical products.